<DOC>
	<DOCNO>NCT02269280</DOCNO>
	<brief_summary>The goal clinical research study compare 2 different drug , decitabine azacitidine , give short standard dosing schedule , may help control MDS . The safety study drug give schedule also study .</brief_summary>
	<brief_title>Phase II Decitabine ( DAC ) Versus Azacitidine ( AZA ) Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>Study Groups Study Drug Administration : Each cycle approximately 28 day . If find eligible take part study , randomly assign ( roll dice ) 1 4 group : - If Group 1 , receive decitabine vein 1 hour Days 1-3 every cycle . - If Group 2 , receive azacitidine either injection skin vein Days 1-3 every cycle . - If Group 3 , receive azacitidine either injection skin vein Days 1-5 every cycle . - If Group 4 , receive standard care . The study doctor explain treatment receive risk involve . Transfusion-dependent participant randomly assign 1 3 group This do one know one study group well , , bad group . If among first 20 participant , equal chance group . If enroll , high chance assign group well result . However , assign group , allow change group . You may give drug help prevent side effect . The study staff tell drug , give , possible risk . Study Visits : One ( 1 ) time month , blood ( 2 tablespoon ) draw routine test . At end Cycle 2 , every 3 cycle first year , every 6 cycle , bone marrow biopsy and/or aspirate check status disease cytogenetic testing . After Cycle 1 , study doctor decide acceptable , may allow receive treatment local cancer doctor . However , must return Houston least every 3 cycle study visit . How often visit occur depend doctor think best interest . Length Study : You may continue take study drug standard therapy long doctor think best interest . You longer able take study drug standard therapy disease get bad , intolerable side effect occur , unable follow study direction . Follow-Up : When off-treatment , every 6 -12 month 5 year , call member study staff . You ask side effect may . The phone call take 5-10 minute . This investigational study . Decitabine azacitidine FDA approve commercially available use patient MDS . Giving drug different schedule standard consider investigational . The study doctor tell study drug design work . Up 240 participant enrol multicenter study . Up 120 take part MD Anderson .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<criteria>1 . Sign IRBapproved inform consent document . 2 . Age &gt; /= 18 year . 3 . IPSS low intermediate1risk MDS , include CMML1 4 . ECOG performance status &lt; /= 3 study entry . 5 . Organ function define : Serum creatinine &lt; /= 2 mg/dL ; Total bilirubin &lt; /= 2 x ULN ; ALT ( SGPT ) &lt; /= 2 x ULN ; AST ( SGOT ) &lt; /= 2 x ULN 6 . Women childbearing potential must negative serum urine pregnancy test within 7 day also need use contraceptive . Men must agree father child agree use condom partner child bear potential . 1 . Breast feeding female 2 . Prior therapy decitabine azacitidine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Low intermediate-1 risk</keyword>
	<keyword>Transfusion-dependent</keyword>
	<keyword>Transfusion-independent</keyword>
	<keyword>Best supportive care</keyword>
	<keyword>BSC</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>5-Azacytidine</keyword>
	<keyword>5-AZA</keyword>
	<keyword>Vidaza</keyword>
	<keyword>5-AZC</keyword>
	<keyword>AZA-CR</keyword>
	<keyword>Ladakamycin</keyword>
	<keyword>NSC-102816</keyword>
	<keyword>Azacytidine</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Dacogen</keyword>
</DOC>